Brief: Alzamend Neuro Announces Date For Delivery Of Topline Data For Phase 1 First-In-Human Clinical Trial For Al001 For Dementia Related To Alzheimer's
30/11/2021 13:35
Nov 30 (Reuters) - Alzamend Neuro Inc ALZN.O :
* ALZAMEND NEURO ANNOUNCES DATE FOR DELIVERY OF TOPLINE DATA
FOR
PHASE 1 FIRST-IN-HUMAN CLINICAL TRIAL FOR AL001 FOR DEMENTIA
RELATED TO ALZHEIMER'S
* ALZAMEND NEURO INC - IND SUBMISSION FOR COMBINED AL002
PHASE 1/2
CLINICAL TRIAL EXPECTED IN Q2 OF 2022
Source text for Eikon: ID:nBw3KwcTca
Further company coverage: ALZN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview